chronic gout market insight
DelveInsight’s ‘Chronic Gout–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Chronic Gout, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Chronic Gout market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted CHRONIC GOUT symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Chronic Gout symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2018–2030
Chronic Gout Disease Understanding and Treatment Algorithm
Chronic Gout Overview
Chronic Gout is the most prevalent form of inflammatory arthropathy. Several studies suggest that its prevalence have risen in recent decades. The main symptom of gout is intense joint pain that subsides to discomfort, inflammation, and redness. The condition frequently affects the base of the big toe but can also occur in the forefoot, ankles, knees, elbows, wrists, and fingers.
Numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronic renal disease.
Common medications include nonsteroidal anti-inflammatory drugs and corticosteroids, another anti-inflammatory. These reduce swelling and pain in the areas affected by gout.
Chronic Gout Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Chronic Gout market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Chronic Gout market report gives a thorough understanding of Chronic Gout symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Chronic Gout symptoms of treatment algorithms and treatment guidelines for Chronic Gout symptoms in the US, Europe, and Japan.
Chronic Gout Epidemiology
The epidemiology division’s Chronic Gout symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Chronic Gout epidemiology segmented as the total Prevalent Cases of Gout, total Prevalent Cases of Chronic Gout, gender-specific prevalent cases of Chronic Gout, prevalence of Chronic Gout based on Risk factors. The report includes the prevalent Chronic Gout scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- Chronic Gout Epidemiology
The epidemiology segment also provides the Chronic Gout epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM prevalent cases of Chronic Gout were 2,355,233 in 2018.
Chronic Gout Drug Chapters
The drug chapter segment of the Chronic Gout report encloses the detailed analysis of Chronic Gout marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Chronic Gout clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Products detail in the report…
Chronic Gout Emerging Drugs
ABP 671: Jiangsu Atom Bioscience and Pharmaceutical
ABP-671 (URAT1), a member of the OAT (organic anion transporter) family, is an anion-exchanging uptake transporter localized to the apical (brush border) membrane of renal proximal tubular cells, where it mediates the re-absorption of uric acid from the proximal tubule, thereby playing a key role in uric acid homeostasis.
The molecular mechanism of action of ABP-671 (URAT1) inhibitors is unknown. Some compounds competitively inhibit URAT1-mediated urate transport in a, suggesting inhibition through interaction with an undefined substrate recognition site.
Products detail in the report…
Chronic Gout Market Outlook
The Chronic Gout market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Chronic Gout market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Chronic Gout market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Chronic Gout market in 7MM is expected to change in the study period 2018–2030.
Key Findings
This section includes a glimpse of the Chronic Gout market in 7MM. The market size of Chronic Gout in the seven major markets was found to be USD 2,405.3 Million in 2018.
The United States Market Outlook
This section provides a total of Chronic Gout market size and market size by therapies in the United States.
The United States accounts for the highest CHRONIC GOUT market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Chronic Gout market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Chronic Gout market size and market size by therapies in Japan are also mentioned.
Chronic Gout Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Chronic Gout market uptake by drugs, patient uptake by therapies, and drug sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.
Chronic Gout Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Chronic Gout key players involved in developing targeted therapeutics.
Major players include ABP 671 (Jiangsu Atom Bioscience and Pharmaceutical), AR-882 (Arthrosi Therapuetics), TMX-049 (Teijin Limited) etc being assessed as potential therapies to be available in the market in the coming future.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Chronic Gout emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working Chronic Gout domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Chronic Gout market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Chronic Gout Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Chronic Gout explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
- Comprehensive insight has been provided into the Chronic Gout epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Gout is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Chronic Gout market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Chronic Gout market
Report Highlights
- In the coming years, Chronic Gout market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Gout R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Chronic Gout. The launch of emerging therapies will significantly impact the Chronic Gout market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Gout.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Chronic Gout Report Insights
- Patient Population
- Therapeutic Approaches
- Chronic Gout Pipeline Analysis
- Chronic Gout Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Chronic Gout Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Chronic Gout Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Chronic Gout Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Chronic Gout Market share (%) distribution in 2018, and how would it look in 2030?
- What would be the Chronic Gout total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
- What are the market’s key findings across 7MM, and which country will have the largest Chronic Gout market Size during the forecast period (2021–2030)?
- At what CAGR, the Chronic Gout market is expected to grow by 7MM during the forecast period (2021–2030)?
- What would be the Chronic Gout market outlook across the 7MM during the forecast period (2021–2030)?
- What would be the Chronic Gout market growth till 2030, and what will be the resultant market Size in the year 2030?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and unmet needs of Chronic Gout?
- What is the historical Chronic Gout patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Chronic Gout in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM concerning the patient population about Chronic Gout?
- Out of all 7MM countries, which country would have the highest prevalent Chronic Gout population during the forecast period (2021–2030)?
- At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Chronic Gout?
- What are the current treatment guidelines for treating Chronic Gout in the USA, Europe, and Japan?
- What are the Chronic Gout marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Chronic Gout?
- How many therapies are developed by each company for the treatment of Chronic Gout?
- How many emerging therapies are in the mid-stage and late development stages to treat Chronic Gout?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Gout therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Gout and their status?
- What are the key designations that have been granted for the emerging therapies for Chronic Gout?
- What are the global historical and forecasted markets of Chronic Gout?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Chronic Gout market
- To understand the future market competition in the Chronic Gout market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Chronic Gout in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Chronic Gout market
- To understand the future market competition in the Chronic Gout market
